EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[Diffuse Large B-cell Lymphoma] - ðû

2022-9-28 À±»óÀº ±³¼ö´Ô °­ÀÇ

1. Introduction

2. Pathology of DLBCL

3. Gastric DLBCL

4. Small bowel DLBCL

5. Colonic DLBCL

6. CAR T-cell therapy

7. References


1. Introduction to DLBCL

1) Histologic types of the localized primary gastric lymphoma (German multicenter study, J Clin Oncol 2005)

Histological typesFrequency (%)
Diffuse large B cell lymphoma
  with small cell component (18.1%)
  without small cell component (81.9%)
59.5
MALT lymphoma37.9
T-cell lympoma1.3
Mantel cell lymphoma0.8
Follicular lymphoma0.5

2022-9-28 À±»óÀº ±³¼ö´Ô °­ÀÇ


2. Pathology of DLBCL

The lymphoma cells diffusely infiltrate or completely destroy the gastric glands. The cells are large with abundant cytoplasam, vesicular nuclei, and occasionally prominent nucleoli. The centroblastic DLBCL cells have vesicular nuclei with multiple nuclear membrane-associated small nucleoli (chromatin margination), whereas the immunublastic variants display a single centrally located prominent nucleolus in most of the cells.

Transformed MALT lymphomas are chracteristically BCL2 and CD10 negative but, in contrast to MALT lymphoma, usually express BCL6. Primary gastric DLBCL, on the other hand, may be CD10 positive and a proportion are BCL2 positive. While CD10- and BCL2-positivity favor de novo DLBCL, CD10- and BCL2-negativity, commonly seen in large B cell transformation of MALToma, cannot completely exclude de novo DLBCL.

YouTube link

pathologyoutlines.com

pathologyoutlines.com


3. Endoscopic findings of the gastric DLBCL

¿©±â¸¦ Âü°íÇϼ¼¿ä.


4. Small bowel DLBCL

[Intussusception due to small bowel lymphoma. ¼ÒÀå ¸²ÇÁÁ¾¿¡ ÀÇÇÑ ÀåÁßøÁõ]

¿©ÀÚ 60¼¼. º¹ÅëÀ¸·Î CT °Ë»çÇÏ¿© ÀÌ»ó¼Ò°ß ¹ß°ß. Æǵ¶: Hepatic flexure colon¿¡ 4.9cm Å©±âÀÇ malignat mass°¡ ÀÖÀ¸¸ç ÀÌ°ÍÀÌ leading point°¡ µÇ¾î À¯µµµÈ ileocecal intussuscptionÀÌ ÀÖÀ½. º´º¯Àº homogeneousÇÑ enhancement¸¦ º¸À̸ç ileocecal mesenteryÀÇ massive lymphadenopathy¸¦ °í·ÁÇÒ ¶§ lymphoma °¡´É¼ºÀÌ °¡Àå ¸ÕÀú °í·ÁµÊ.

³»½Ã°æ µµÁß hepatic flexure±îÁö µ¹ÃâµÈ º´º¯ÀÌ ¼ÒÀåÀ¸·Î ¹Ð·Áµé¾î°¨. ¼ÒÀå mass·Î ÀÎÇÑ intussusceptionÀÓ. Á¶Á÷°Ë»ç: atypical blue cell. lymphoid ȤÀº NET ±â¿ø °¡´É¼º.

CD20


RLQ pain°ú ¹ß¿­·Î CT °Ë»ç¸¦ ÅëÇÏ¿© Á¾¾çÀÌ ¹ß°ßµÇ¾ú½À´Ï´Ù. ¼ö¼úÀ» ÇÏ¿´½À´Ï´Ù.


Diffuse large B cell lymphoma
1. Location: small bowel
2. Gross type: ulcerofungating
3. Size: 4.5x4 cm
4. Depth of invasion: invades subserosa (pT3)
5. Resection margin: free from malignant lymphoma - safety margin: proximal, 7 cm ; distal, 4.5 cm
6. Regional lymph node metastasis : No metastasis in all regional lymph nodes(pN0)
7. Lymphatic invasion: not identified
8. Venous invasion: not identified
9. Perineural invasion: present(intramural)
10. Tumor border: infiltrative
11. Associated findings : perforation
12. Pathologic staging: pT3 N0


º¹ÅëÀ¸·Î ½ÃÇàÇÑ CT¿¡¼­ mass°¡ ¹ß°ßµÇ¾î ³»½Ã°æ °Ë»ç¿¡¼­ diffuse large B cell lymphoma°¡ È®ÀÎµÇ¾î ¼ö¼úÀ» ÇÏ¿´½À´Ï´Ù.


Ascending colon, cecum, appendix, and terminal ileum, right hemicolectomy: Diffuse large B-cell lymphoma, not otherwise specified, activated B-cell type
1. Location: terminal ileum
2. Gross type: bulky transmural mass
3. Size: 13x8.5 cm
4. Depth of invasion: directly invades adjacent soft tissue including bladder serosa and peritoneum
5. Resection margin: free from lymphoma, safety margin: nearest, 5.5 cm ; opposite, 5.0 cm
6. Regional lymph node metastasis : No metastasis


5. Colonic DLBCL


6. CAR T-cell therapy

1) Diffuse large B cell lymphomaÀÇ Ä¡·á 2022-9-28 »ï¼º¼­¿ïº´¿ø Á¾¾ç³»°ú À±»óÀº ±³¼ö´Ô

2) »ï¼º¼­¿ïº´¿ø Youtube

3) 2022-11-19. »ï¼º¼­¿ïº´¿ø ¾Ïº´¿ø ½ÉÆ÷Áö¾ö. CAR T-cell therapy


[References]

1) EndoTODAY À§ DLBCLÀÇ ³»½Ã°æ ¼Ò°ß

2) Diffuse large B cell lymphomaÀÇ Ä¡·á (°ü¸®ÀÚ Àü¿ë) 2022-9-28 »ï¼º¼­¿ïº´¿ø Á¾¾ç³»°ú À±»óÀº ±³¼ö´Ô

3) Classification of lymphomas

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng